ABD and its predecessors have been registered with and inspected by the US Food & Drug Administration since 1976. Our original diaphragm pacing system received premarket approval status from the FDA immediately upon requirement in 1986, with the latest modifications approved in March 2003. FDA premarket approval is required before Class III medical devices can be commercially distributed in the United States. The Avery Diaphragm Pacing System is the only device with such approval.
The premarket approval number for the Diaphragm Pacing System is P860026. The FDA Center for Devices and Radiological Health has assigned diaphragmatic/phrenic nerve stimulators the product code 84GZE under CFR 882.5830.
European Community (EU Countries, Switzerland and Norway)
Avery Biomedical Devices holds certificate number FM 547851 and operates a Quality Management System which complies with the requirements of ISO 13485: 2016 for the design and development, production and servicing of implanted diaphragm pacemaker systems.
The Avery Diaphragm Pacing System has been registered with the Administractión Nacional de Medicamentos Alimentos y Tecnologia Médica since June 2010.
The Avery Diaphragm Pacing System has been registered with the Israel Ministry of Health – Medical Technology, Information and Research Division (Medical Devices Department).
Our authorized representative is Lowenstein-Weinmann Medical Israel Ltd.